J. Sieper

3.1k citations
84 papers · 2.3k indexed · h-index 18

J. Sieper

78 papers receiving 2.2k citations

Peers

J. Sieper
Comparison fields: 5 of 87
  • Rheumatology 1.7k
  • Hematology 611
  • Immunology 897
  • Orthopedics and Sports Medicine 223
  • Dermatology 96
Replace U. Eggens with:
U. Eggens Germany
H. Sörensen Germany
Elisabeth Märker‐Hermann Germany
B.A.C. Dijkmans Netherlands
Naoto Tamura Japan
R. Saario Finland
Max Hamburger United States
C. J. Elson United Kingdom
Alain Chevailler France
Barry L. Myones United States
J. Sieper relative to U. Eggens Germany U. Eggens's profile →
Citations per field
00.5×1.7×
U. Eggens · 1×
Citations per year

Countries citing papers authored by J. Sieper

Since Specialization
Citations

This map shows the geographic impact of J. Sieper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Sieper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Sieper more than expected).

Fields of papers citing papers by J. Sieper

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Sieper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Sieper. The network helps show where J. Sieper may publish in the future.

Co-authorship network

The 25 scholars most cited alongside J. Sieper, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J. Sieper Line = papers co-authored together J. Sieper links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20242
3 20241
4
Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels: Pooled Analysis of Two Phase 3 Studies
20170
5
LONG-TERM EFFICACY AND TOLERABILITY OF GOLIMUMAB IN ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS : RESULTS OF THE OPEN-LABEL EXTENSION OF A RANDOMIZED, DOUBLE-BLIND STUDY
20161
6
Effect of Certolizumab Pegol Over 48 Weeks in Patients with Axial Spondyloarthritis, including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
20143
7
LONG-TERM SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 96-WEEK OUTCOMES OF THE RAPID-AXSPA TRIAL
20141
8
Observed Incidence Rates of Uveitis over 96 Weeks of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis.
20141
9
CLINICAL RESPONSE AND REMISSION IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AFTER THREE YEARS OF ADALIMUMAB THERAPY
20142
10
SUSTAINED EFFICACY OF ADALIMUMAB IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH POSITIVE MRI OF THE SACROILIAC JOINTS OR SPINE OR ELEVATED C-REACTIVE PROTEIN AT BASELINE
20131
11
Safety and Efficacy Of Etanercept In Early Non-Radiographic Axial Spondyloarthritis : A Randomized, Double-Blind, Placebo-Controlled Trial At 24 Weeks
20133
12
Improvement in Signs and Symptoms of Active Ankylosing Spondylitis Following Treatment with Anti-Interleukin (IL)-17A Monoclonal Antibody Secukinumab Are Paralleled by Reductions in Acute Phase Markers and Inflammatory Markers S100A8 and A9 (Calgranulin A and B)
20122
13
Long Term Inhibition of Interleukin (IL)-17A with Secukinumab Improves Clinical Symptoms and Reduces Spinal Inflammation As Assessed by Magnetic Resonance Imaging in Patients with Ankylosing Spondylitis.
20124
14
Effect of Certolizumab Pegol On Signs and Symptoms of Ankylosing Spondyltitis and Non-Radiographic Axial Spondyloarthritis : 24 Week Results of a Double Blind Randomized Placebo-Controlled Phase 3 Axial Spondyloarthritis Study
201210
15
Concurrent sacroiliac joint and spinal inflammation on Mri in patients with non-radiographic axial spondyloarthritis
20121
16
Efficacy and Safety of Adalimumab in Patients with Non-Radiographic Axial Spondyloarthritis - Results From a Phase 3 Study
20116
17
Description of spinal MRI lesions and definition of a positive MRI of the spine in axial SpA
20103
18
Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-term efficacy and safety in AS (ATLAS)
20082
19
Die glukokortikoidinduzierte Osteoporose
20012
20 200178

About J. Sieper

J. Sieper is a scholar working on Rheumatology, Orthopedics and Sports Medicine and Immunology, having authored 84 papers that have together received 2.3k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (60 papers), Spondyloarthritis Studies and Treatments (57 papers), Psoriasis: Treatment and Pathogenesis (17 papers), Bone and Joint Diseases (10 papers), Autoimmune and Inflammatory Disorders Research (9 papers), Systemic Lupus Erythematosus Research (9 papers), Spine and Intervertebral Disc Pathology (6 papers) and Fibromyalgia and Chronic Fatigue Syndrome Research (4 papers). The work is most often cited by research in Rheumatology (1.7k citations), Hematology (611 citations) and Immunology (897 citations). J. Sieper has collaborated with scholars based in Germany, United States and Canada. Frequent co-authors include Anna Katharina Simon, Eva Seipelt, Jürgen Braun, Jürgen Braun, Hildrun Haibel, M. Bollow, J. Brandt, U. Eggens, Wolfgang Thriene and J. González. Their work appears in journals such as Annals of the Rheumatic Diseases, Clinical and Experimental Rheumatology, Lara D. Veeken, Immunology Letters and Osteoporosis International.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026